--- title: "AI-designed drug rentosertib shows potential to reduce biological age markers" publication: "MediaBias News" url: "https://mediabias.news/health/ai-designed-drug-rentosertib-shows-potential-to-reduce-biological-age-markers" api: "https://mediabias.news/api/v1/stories/ai-designed-drug-rentosertib-shows-potential-to-reduce-biological-age-markers" markdown: "https://mediabias.news/health/ai-designed-drug-rentosertib-shows-potential-to-reduce-biological-age-markers.md" audio: "https://mediabias.news/api/audio/ai-designed-drug-rentosertib-shows-potential-to-reduce-biological-age-markers" category: "Health" published: "2026-09-07T19:05:13.581Z" source_reported: "2026-09-07T18:23:00.000Z" updated: "2026-09-07T19:05:13.581Z" trust_score: 50 critic_score: 65 hype_score: 45 assessment_type: "coverage-and-source-reporting-analysis" fact_check_status: "not-performed" coverage_measured: "2026-09-07T20:15:06.937109+00:00" --- # AI-designed drug rentosertib shows potential to reduce biological age markers *Secondary analysis of a phase 2a study suggests the drug may make patients appear biologically younger.* **Scores for the source reporting** (0-100, assessing the original journalism this article was written from, not this write-up): - Trust 50 of 100, higher is better. Central claim attributed to Insilico Medicine, with a secondary analysis published in Nature Biotechnology. - Craft 65 of 100, higher is better. Reports include quotes from the CEO and explain the study's methodology and limitations. - Hype 45 of 100, lower is better. Headlines and digests suggest reversal of aging, while the full report notes limitations and alternative explanations. Scored by MediaBias News; method at https://mediabias.news/methodology. **The short version** - Insilico Medicine's drug rentosertib, developed using generative AI, was analysed in a secondary study of 42 patients with idiopathic pulmonary fibrosis. - Six independent aging clocks indicated that patients treated with rentosertib appeared biologically younger than those receiving a placebo. - The most significant effect was observed in the 30mg twice-daily dosage group, where patients appeared 2.7 to 3.5 years younger on certain clocks at week four. - Study authors cautioned that the results cannot yet distinguish between slower aging and the effect of treating an inflammatory lung condition. Insilico Medicine's drug rentosertib, designed with generative artificial intelligence, was the subject of a secondary analysis of a phase 2a study involving 42 patients with idiopathic pulmonary fibrosis. Proteomic data from these patients were analysed using six independent aging clocks. These analyses indicated that patients treated with rentosertib appeared biologically younger than those in the placebo group. The largest observed effect was in the group receiving 30mg of rentosertib twice daily. At week four, these patients appeared 2.7 to 3.5 years younger on certain aging clocks. Alex Zhavoronkov, co-CEO of Insilico Medicine, stated that extending the healthy portion of life by three years could translate into significant productivity and savings. The study authors noted a significant caveat: the results cannot yet definitively separate slower aging from the effects of treating the lung condition itself, as idiopathic pulmonary fibrosis is an inflammatory disease. They attempted to address this by showing that the 30mg twice-daily arm reversed age-associated protein patterns while the placebo group followed a normal aging trajectory, though this was considered suggestive rather than conclusive. ## Disagreement on effect size While the TNM report stated that the largest effect observed was between 2.7 and 3.5 years younger on certain clocks at week four, Insilico's own summary of the work described roughly three to four years, and up to six on certain clocks. The ZN.UA report stated that the average biological age of participants decreased by approximately six years after four weeks of the first dose. ## What the coverage left out None of the left or centre-rated reports mentioned the specific figure of 55,319 UK Biobank profiles used as a reference population in the proteomic analysis, as detailed in the TNM full report. Additionally, none of the centre-rated digests mentioned the seven patients who discontinued the trial due to liver toxicity, a detail present in the TNM full report. ## Who covered it Shares of the 8 covering outlets with a published leaning rating: - Left: 13% (1) - Centre: 87% (7) - Right: 0% (0) 8 of 16 covering outlets carried no usable leaning rating and were excluded from those percentages. Coverage measured 2026-09-07T20:15:06.937109+00:00. **Coverage watch:** developing. Checked 7 times; 0 checks found a material change. Most recently checked 2026-09-07T20:45:05.887Z. ## How the sides framed it ### Left - The single left-rated report, from TNM, led with the finding that AI-designed rentosertib lowered biological age markers in a 42-patient trial. It detailed the use of six independent aging clocks and quoted Alex Zhavoronkov, co-CEO of Insilico Medicine, stating that adding three years to everyone's life could significantly extend the healthy portion of life. The report also highlighted the study's limitations, noting that it could not yet separate slower aging from a treated lung, and that proteomic aging scores are not a regulatory endpoint for drug approval. It mentioned that rentosertib entered phase 3 trials in July. ### Centre - The centre-rated reports focused on Insilico's AI-developed drug candidate showing anti-aging potential. Several digests, including MarketWatch, Wall Street Journal, News Medical, Bloomberg, and PR Newswire, highlighted that the drug rentosertib, designed with AI, demonstrated potential for biological age reversal. The ZN.UA report, which included a full article, stated that the drug reduced patients' biological age by approximately six years, quoting Insilico's CEO Alex Zhavoronkov on the potential to extend healthy life. The AI Journal and PR Newswire digests noted this was the first de-novo drug designed with generative AI for a de-novo target discovered using AI, and highlighted the consensus across six independently-developed proteomic aging clocks. Bloomberg and BizToc digests reported that the AI-discovered drug reversed aging markers in a study, according to the biotech company. ### Right No separate framing summary. ## Factuality profile of the covering outlets These are published factuality ratings of the outlets, not a verdict on whether this story or its claims are true. - high: 6 - unknown: 8 - veryHigh: 2 ## Verification scope This page compares coverage and scores the source reporting. It is not a ClaimReview verdict on whether the underlying event or claim is true. ## Original reporting this was written from - [MarketWatch](https://marketwatch.com/story/insilico-ai-developed-drug-candidate-shows-anti-aging-potential-in-new-study-e417967a?mod=markets) — Insilico AI-Developed Drug Candidate Shows Anti-Aging Potential in New Study - [Wall Street Journal](https://wsj.com/tech/biotech/insilicos-co-ceo-has-big-hopes-that-fibrosis-drug-can-reverse-aging-too-1c5bf5a6) — Insilico’s Co-CEO Has Big Hopes That Fibrosis Drug Can Reverse Aging Too - [The Decoder](https://the-decoder.com/ai-designed-drug-appears-to-turn-back-the-bodys-biological-clock-in-early-trial) — AI-designed drug appears to turn back the body's biological clock in early trial - [the-decoder.de](https://the-decoder.de/ki-designter-wirkstoff-zeigt-hinweise-auf-biologische-verjuengung) — AI-Designed Active Substance Shows Evidence of Biological Rejuvenation - [Insider Paper](https://insiderpaper.com/ai-generated-drug-rentosertib-slow-aging) — AI-generated drug could potentially slow aging, study says - [News Medical](https://news-medical.net/news/20260907/AI-designed-drug-candidate-reverses-biological-age-in-clinical-study.aspx) — AI-designed drug candidate reverses biological age in clinical study - [FuturoProssimo](https://futuroprossimo.it/2026/09/primi-risultati-del-farmaco-insilico-per-invecchiare-piu-lentamente) — First Results of the Insilic Drug to Get Older More Slowly - [TNW](https://thenextweb.com/news/insilico-rentosertib-proteomic-aging-clocks) — Insilico says its AI-designed lung drug lowered biological age markers in a 42-patient trial - [ZN.UA Зеркало недели](https://zn.ua/TECHNOLOGIES/ii-pomoh-sozdat-preparat-kotoryj-snizil-biolohicheskij-vozrast-patsientov-na-shest-let.html) — YI Helped Create a Drug that Reduced the Biological Age of Patients by Six Years. - [The AI Journal](https://aijourn.com/nature-biotechnology-insilicos-ai-driven-ipf-candidate-rentosertib-shows-potential-for-biological-age-reversal-as-assessed-by-six-proteomic-aging-clocks) — Nature Biotechnology | Insilico's AI-Driven IPF Candidate Rentosertib Shows Potential for Biological Age Reversal, as Assessed by Six Proteomic Aging Clocks - [PR Newswire](https://prnewswire.com/news-releases/nature-biotechnology--insilicos-ai-driven-ipf-candidate-rentosertib-shows-potential-for-biological-age-reversal-as-assessed-by-six-proteomic-aging-clocks-302871277.html) — Insilico's AI-Driven IPF Candidate Rentosertib Shows Potential for Biological Age Reversal, as Assessed by Six Proteomic Aging Clocks - [Startup Fortune](https://startupfortune.com/newlimit-says-its-ai-system-reversed-aging-signs-in-human-liver-cells) — NewLimit Says Its AI System Reversed Aging Signs in Human Liver Cells - [Bloomberg](https://bloomberg.com/news/articles/2026-09-07/ai-discovered-drug-reverses-aging-markers-in-study-biotech-says) — AI-Discovered Drug Reverses Aging Markers In Study, Biotech Says - [Crypto Briefing](https://cryptobriefing.com/insilico-medicine-rentosertib-aging-phase-three) — Insilico Medicine's rentosertib shows potential to slow aging in landmark Phase III trial - [Cryptocurrency News | Cryptocurrency Prices | Market Cap](https://cryptocurrency.com.tr/insilico-medicines-rentosertib-shows-potential-to-slow-aging-in-landmark-phase-iii-trial-368289) — Insilico Medicine’s rentosertib shows potential to slow aging in landmark Phase III trial - [BizToc](https://biztoc.com/x/de079f3e633b2c06) — AI-Discovered Drug Reverses Aging Markers in Study, Biotech Says ## Questions **What is rentosertib and how was it developed?** Rentosertib is a drug developed by Insilico Medicine using generative artificial intelligence. It is being tested as a treatment for idiopathic pulmonary fibrosis, a lung disease. The AI was used to identify a target and then to design and optimise molecules. **What did the study on rentosertib find regarding aging?** A secondary analysis of a phase 2a study involving 42 patients indicated that those treated with rentosertib appeared biologically younger than those on placebo, according to six independent aging clocks. The largest effect showed patients appearing 2.7 to 3.5 years younger on certain clocks at week four. **What are the limitations of these findings?** Study authors cautioned that the results cannot yet definitively separate slower aging from the effects of treating the inflammatory lung condition, idiopathic pulmonary fibrosis. They also noted that proteomic aging scores are not a regulatory endpoint for drug approval. --- MediaBias News — https://mediabias.news. Reproduced from https://mediabias.news/health/ai-designed-drug-rentosertib-shows-potential-to-reduce-biological-age-markers. Please cite as: MediaBias News, "AI-designed drug rentosertib shows potential to reduce biological age markers", https://mediabias.news/health/ai-designed-drug-rentosertib-shows-potential-to-reduce-biological-age-markers